Evaluation of tumor‑free distance and depth of myometrial invasion as prognostic factors in endometrial cancer

  • Authors:
    • Raoudha Doghri
    • Salma Chaabouni
    • Yoldez Houcine
    • Lamia Charfi
    • Nadia Boujelbene
    • Maha Driss
    • Karima Mrad
  • View Affiliations

  • Published online on: May 16, 2018     https://doi.org/10.3892/mco.2018.1629
  • Pages: 87-91
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the study was to investigate whether the tumor free distance (TFD), which is the distance in millimeters between the deepest point of invasion and the serosal surface, and absolute depth of invasion (DMI), the distance in millimeters between the endomyometrial junction and the deepest point of myometrial invasion, are useful in surgical staging and in predicting prognosis. The present study retrospectively analyzed 62 cases of endometrial carcinoma with complete surgical staging, carried out over a 4 and half‑year period (January 2003 to June 2007). All surgicopathological findings including surgical stages, histological type and grade, myometrial invasion, lymphovascular space invasion, cervical and adnexal involvement, and lymph node metastasis were abstracted from medical records and pathological reports. Univariate and multivariate analyses were performed comparing TFD, DMI and the percentage of mypmetrial invasion (MI) with established prognostic factors. A total of 62 patients were included in the study. A total of 52 (84%) had endometrioid carcinomas and 31 patients (60%) had grade 1 cancer. The deepest MI was <50% in 32 patients (52%). Median DMI was 2.7 mm (range 0‑15 mm). Median TFD was 3 mm (range 0‑19 mm). There was lymphovascular space invasion (LVSI) in 11 patients (17.5%), cervical involvement in 11 patients (17.5%), extra‑uterine extension in 9 cases (14%) and lymph node metastasis in 12 patients (22%). It was demonstrated that 50% MI was significantly associated with prognostic factors (cervical involvement, type 2 carcinomas and LVSI, and was a significant predictor of the 5‑year overall survival rate and recurrence‑free survival (P=0.05, P=0.01). No significant association was observed between DMI and TFD with clinicopathological parameters and survival rates. The importance of DMI in predicting recurrence of disease was observed to be highest in terms of sensitivity and specificity. The cut‑off value with the highest sensitivity and specificity crossing the receive operating characteristic curve was calculated to be 3 mm for DMI and 2.5 mm for TFD. The results indicate that DMI is a superior predictive factor of recurrence of the disease compared with TFD. However, further studies are required in order to prove the prognostic usefulness of these parameters and then to improve management of endometrial cancer.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 9 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Doghri R, Chaabouni S, Houcine Y, Charfi L, Boujelbene N, Driss M and Mrad K: Evaluation of tumor‑free distance and depth of myometrial invasion as prognostic factors in endometrial cancer. Mol Clin Oncol 9: 87-91, 2018.
APA
Doghri, R., Chaabouni, S., Houcine, Y., Charfi, L., Boujelbene, N., Driss, M., & Mrad, K. (2018). Evaluation of tumor‑free distance and depth of myometrial invasion as prognostic factors in endometrial cancer. Molecular and Clinical Oncology, 9, 87-91. https://doi.org/10.3892/mco.2018.1629
MLA
Doghri, R., Chaabouni, S., Houcine, Y., Charfi, L., Boujelbene, N., Driss, M., Mrad, K."Evaluation of tumor‑free distance and depth of myometrial invasion as prognostic factors in endometrial cancer". Molecular and Clinical Oncology 9.1 (2018): 87-91.
Chicago
Doghri, R., Chaabouni, S., Houcine, Y., Charfi, L., Boujelbene, N., Driss, M., Mrad, K."Evaluation of tumor‑free distance and depth of myometrial invasion as prognostic factors in endometrial cancer". Molecular and Clinical Oncology 9, no. 1 (2018): 87-91. https://doi.org/10.3892/mco.2018.1629